Non-infectious Vaccines
The success of Millicom gave Kimberlin the credibility to start his first company with renowned polio hero, Dr. Jonas Salk.
As the founder of The Immune Response Corporation, Kimberlin drove the strategy, recruited the management and scientific teams, and brought together its major corporate partners to advance Dr. Salk’s groundbreaking immunotherapeutics.
Immune Response cemented Kimberlin’s reputation as a high-impact entrepreneur when it became the best-performing U.S. stock in 1991.
Their Phase III vaccine trial, incorporating 2,527 HIV-infected patients (the largest immunotherapy trial conducted to that point), unfortunately, failed to meet its clinical endpoint, a devastating personal loss to Kimberlin. Yet he derived comfort by exchanging the company’s B-cell lymphoma patent for stock in a startup backed by Microsoft co-founder, Paul Allen. This patent was key to the first FDA-approved immune-based cell therapy – the prostate cancer vaccine that appears to be more effective in African-American men with a 48% reduction in death compared to white men.
The plant and the team that makes the cancer vaccine also made the clinical and initial commercial supply of the first FDA-approved gene therapy (the CAR-T therapy Kymriah from Novartis).
Social Impact
Kevin Kimberlin also supports social progress through charitable activities and gives to a variety of civil organizations.
Kevin gives to a variety of organizations including the Harvard University Innovation Lab, BeyondPolio, and the Jonas Salk Legacy Foundation (to support its efforts for the eradication of polio worldwide), the Audubon Society (for its citizen-science and conservation programs), and Yaddo, the creative artist community, where he is an Honorary Lifetime Member in recognition of his support of writers, choreographers, dancers, playwrights and composers.
Kevin graduated from Indiana University and earned his Masters from Harvard University. He lets his actions speak for themselves, embracing Mr. Spencer Trask’s motto: “Deeds, not words.”